Brɔst kansa na sɔntin we kin mek bɔku uman dɛn fred. Ɛspɛshali afta we uman dɔn lɛf fɔ gɛt bɛlɛ, dat na afta we di mɔnt dɔn stɔp, bɔku pipul dɛn kin tink bɔt dis prɔblɛm. So, tide wi de tɔk bɔt wan mɛrɛsin we de ɛp uman dɛn we de pan risk fɔ dis kayn kansa fɔ ridyus da risk de. Dɛn kɔl dis drɔg Evista. Di aktif tin we de insay am na raloxifene. Dɛn kin yuz am fɔ ridyus di risk fɔ gɛt bɔdi kansa , ɛn fɔ ridyus di risk fɔ brok brok we kin kam bikɔs ɔf ɔstioporosis, we na wan sik we kin mek yu bon tan we kin apin afta yu dɔn menɔpauz.
Wetin rili na invasive breast cancer?
Fɔs, lɛ wi ɔndastand dis simpul wan. Tu men kayn kansa de na di bɔdi. Wan pan dɛn na kansa we nɔ de ambɔg pɔsin. insay dis, di kεnsar sεl dεm de כnli insay di milk dכkt dεm כ di gland dεm we de prodyuz milk (lobules) na di brεst, εn dεn nכ de go pas dεn bכnda dεm de.
Bɔt, invasive breast cancer na wan sik we rili siriɔs. wetin de apin ya na we di kεnsar sεl dεm de brok kכmכt na di milk dakt εn gland dεm εn spre to di hεlty brεst tisu we de rawnd am. Frɔm de, dɛn kin go bak to ɔda pat dɛn na di bɔdi lɛk di liva, di lɔng, ɛn di bren. Dis na di kɔndishɔn we denja pas ɔl. Na dat mek i rili impɔtant fɔ no ɛn trit dɛn kayn kansa ya kwik kwik wan.
Aw Evista kin ridyus di risk fɔ gɛt dis kansa?
di dכg we dεn kכl Evista de pan wan klas dεm we dεn kכl ``SERM (Selective Estrogen Receptor Modulator)''. Fɔ tɔk am simpul wan, dɛn drɔgs ya kin wok lɛk di ɔmon we dɛn kɔl ɛstrojen na sɔm pat dɛn na di bɔdi ɛn dɛn kin wok agens di ɔmon we dɛn kɔl ɛstrojen na ɔda pat dɛn.
As yu go no, ɛstrojen kin ɛp sɔm kayn bɔdi kansa fɔ gro. Jɔs lɛk aw plant nid wata fɔ gro. Evista de wok bay we i de atak di εstrojen risεptor dεm na di brεst tisu, we de blכk di spεs fכ di rial εstrojen כmon fכ atak de. dis min se i de stכp di kεnsar sεl dεm fכ gεt di εstrojen mεsej we dεn nid fכ gro.
Bɔt i impɔtant fɔ mɛmba dis: Evista nɔto tritmɛnt fɔ pɔsin we dɔn ɔlrɛdi gɛt bɔdi kansa. Dɛn nɔ kin gi am bak fɔ mek kansa nɔ kam bak pan pɔsin we dɔn ɔlrɛdi gɛt kansa. Dɛn kin jɔs yuz am fɔ ridyus di risk fɔ gɛt kansa pan uman dɛn we dɛn dɔn no se gɛt am afta dɛn dɔn menɔpauz.
Ɛni sayd ɛfɛkt de we Evista gɛt?
Yɛs. Lɛk ɛni mɛrɛsin, Evista kin gɛt sayd ɛfɛkt. Sɔm na smɔl smɔl tin dɛn, bɔt siriɔs sayd ɛfɛkt dɛn de bak we yu fɔ no bɔt. So, yu fɔ tɔk to yu dɔktɔ bɔt di gud ɛn bad tin dɛn bifo yu disayd fɔ tek dis mɛrɛsin.
| Tayp fɔ di sayd ɛfɛkt | Tɔk bɔt |
|---|---|
| Siriɔs sayd ɛfɛkt dɛn we nid fɔ pe atɛnshɔn wantɛm wantɛm | |
| Blɔd we De Klɔt | di risk fכ blכd kכlכt na di vein dεm na di leg (Deep Vein Thrombosis) εn di lכng (Pulmonary Embolism) kin bכku. |
| Strok | Uman dɛn, mɔ di wan dɛn we gɛt at sik, kin gɛt strok smɔl. |
| Kɔmɔn, nɔr siriɔs sayd ɛfɛkt dɛm | |
| Fɔ mek yu bɔdi nɔ fil fayn | Leg kramp, joyn pen, swel na di limb dɛm. |
| Ɔda prɔblɛm dɛn we kin apin | Di sayn dɛm lɛk fiva, ɔt flash, swet, nɔr kin slip, ɛn vagina dray. |
So udat fit fɔ tek dis mɛrɛsin?
Dis na kwɛstyɔn we rili impɔtant. Evista nɔto wan saiz-fit-ɔl drɔg. Yu dɔktɔ go tɔk to yu bɔt yu pasɔnal wɛlbɔdi istri .Ɛn di tin dɛn we kin mek pɔsin gɛt dis sik kin sho if dis fayn ɔ i nɔ fayn. Jɛnɛral wan, pipul dɛm wae kin bɛnifit mɔr frɔm dis mɛrɛsin na:
- Uman dɛn we dɔn pas 60 ia: Bikɔs di risk fɔ gɛt bɔdi kansa kin bɔku we dɛn de ol.
- Pipul wae dɔn gɛt bɔdi kansa na dɛn famili: mɔr lɛk dɛn fambul lɛk mama ɔr sista.
- Pipul dεm we gεt jεnεtik prεdispכzishכn: If tεst dεn dכn kכnfכm se dεn gεt jεnεtik mכtεshכn lεk BRCA1 εn BRCA2.
- di wan dεm we dεn bin dכn du brεst bayopsi bifo εn dεn bin dכn no se dεn gεt wan kכndyushכn we kin bi di prεkursכr fכ kεnsar, lεk `lobular carcinoma in situ (LCIS).`
- Pipul dεm wae gεt כda risk factor dεm: Fכ egzampl, ol ej we dεn bכn am fכs, let mεnopos, εn כda tin dεm.
Afta yu dɔn tink bɔt ɔl dɛn tin ya, yu dɔktɔ go rili no di prɔblɛm we yu gɛt.
Udat nɔ fɔ tek Evista?
Evista kin du mɔ bad pas gud to uman dɛn we gɛt sɔm wɛlbɔdi prɔblɛm. So, i rili ban fɔ yuz dis mɛrɛsin if yu de pan dɛn grup ya:
- Uman dɛn we gɛt bɛlɛ ɔ we de op fɔ gɛt bɛlɛ.
- Uman dɛn we gɛt blɔd klɔt naw ɔ bifo na dɛn leg, lɔng, ɔ yay.
- uman dεm we de bifo mεnoposal, we min se dεn stil de gεt mכnt mכnt.
- Pipul dɛn we de tek wan mɛrɛsin we de mek dɛn nɔ gɛt bɔku kɔlɔstrel lɛk Cholestyramine.
- di wan dεm we de tek כda εstrojen כmon tritmεnt (supplemental estrogen).
Wetin na di difrɛns bitwin Evista ɛn Tamoxifen?
Yu go dɔn yɛri bak bɔt wan mɛrɛsin we dɛn kɔl Tamoxifen. Na drɔg bak we de na di SERM klas. Stɔdi dɔn sho se dɛn tu mɛrɛsin ya kin wok di sem we fɔ ridyus di risk fɔ gɛt kansa na in bɔdi.
Bɔt sɔm impɔtant tin dɛn de we difrɛn. Dɛn dɔn ripɔt se tamoxifen gɛt fɔ du wit di ay risk fɔ gɛt uterin kansa pas Evista. Dɛn dɔn sho bak se Evista nɔ de protɛkt di kansa dɛn we nɔ de invayd lɛk daktal kansa in situ (DCIS), we Tamoxifen de du am.
Di prɔblɛm dɛn we kin mek pɔsin gɛt blɔd klot ɛn strok na tin we kin apin to dɛn tu mɛrɛsin ya. Sɔm stɔdi dɛn se di risk smɔl wit Evista pas wit Tamoxifen, ɛn ɔda stɔdi dɛn se nɔr big difrɛns nɔ de.
So te go, fɔ disayd uswan pan dɛn tu mɛrɛsin ya go fayn fɔ yu, ɔ if i rili nid fɔ tek dis kayn mɛrɛsin, na tin we yu fɔ tek tɛm tink bɔt afta yu dɔn tɔk bɔt ɔl di gud ɛn bad tin dɛn wit yu dɔktɔ.
Mɛsej we dɛn kin kɛr go na os
- Evista (raloxifene) na mɛrɛsin we dɛn kin gi uman dɛn we gɛt bɔku risk fɔ gɛt bɔdi kansa afta dɛn dɔn menɔpauz fɔ ridyus da risk de . I nɔto mɛrɛsin fɔ kansa.
- Risk de fɔ gɛt siriɔs sayd ɛfɛkt lɛk fɔ blɔd klot ɛn paralayz we yu de yuz dis mɛrɛsin.
- Di disayd fɔ tek dis mɛrɛsin ɔ nɔ tek am na fɔ yusɛf we yu fɔ tek tɛm tɔk to yu dɔktɔ bɔt di tin dɛn we kin mek yu gɛt prɔblɛm ɛn di wɛlbɔdi prɔblɛm.
- Ivin afta dɛn dɔn tek Evista, sɔm uman dɛn kin stil gɛt kansa na dɛn bɔdi, so i impɔtant fɔ kɔntinyu fɔ chɛk dɛnsɛf ɔltɛm na dɛn bɔdi ɛn fɔ mek dɛn tek dɛn mama in bɔdi.
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt